Bone mineral density, metabolic syndrome, and vitamin D in indigenous from south of Brazil

Rocha, Ana Karina Silva da; Bós, Ângelo José Gonçalves; Carnenaz, Guilherme

doi:10.1007/s11657-013-0134-3

Cited by 6 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our analysis, baseline rates of bone disease (osteopenia or osteoporosis) did not vary by 25(OH)D level. In an indigenous, adult Brazilian population, lower 25(OH)D levels also did not predict decreased bone mineral density [ 37 ], but lower high-density lipoprotein cholesterol were associated with lower 25(OH)D levels. Given the known interactions of high-density lipoprotein with osteoclasts and osteoblasts [ 38 ], we assessed this relationship in our cohort, but did not find an association between high-density lipoprotein cholesterol and bone mineral density in the subset of participants who underwent DXA scanning (data not shown).…”

Section: Discussionmentioning

confidence: 99%

Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy

Coelho

Cardoso

Luz

et al. 2015

Nutr J

View full text Add to dashboard Cite

BackgroundHIV infection and antiretroviral therapy (ART) may create unique risk factors for vitamin D insufficiency, including alterations of vitamin D metabolism by ART. We prospectively compared demographic and clinical parameters between vitamin D sufficient and insufficient HIV-infected (HIV+) adults, and assessed changes in these parameters among insufficient participants following standardized vitamin D supplementation.MethodsHIV+ adults (≥18 years old) with HIV-1 RNA <50 copies/mL on ART were enrolled. Vitamin D sufficiency and insufficiency were defined as 25-hydroxyvitamin D (25(OH)D) ≥30 or <30 ng/mL, respectively. Insufficient participants received open-label vitamin D3 50,000 IU twice weekly for 5 weeks, then 8000 IU twice weekly to complete 24 weeks. The primary endpoint was success or failure to achieve 25(OH)D ≥30 ng/mL at week 24.ResultsNinety-seven participants enrolled (34 vitamin D sufficient, 63 insufficient); 32 % female, 47 % non-White, median age 46 years, ART duration 5 years, CD4+ T lymphocyte count (CD4) 673 cells/mm3. 25(OH)D repletion was 83 % (95 % CI 71 %–90 %) successful. 25(OH)D levels correlated with both CD4 (r = 0.44, p = 0.01) and time on protease inhibitor (r = −0.35, p = 0.01). After adjusting for age, sex, race, nadir CD4 and baseline 25(OH)D: 1) current use of efavirenz exposure was associated with a 21.1 ng/mL higher week 24 25(OH)D level (p = 0.007), 2) per year use of zidovudine was associated with 7.1 ng/mL reduction in week 24 serum 25(OH)D (p = 0.05) and 3) every 1 ng/mL 25(OH)D increase was associated with a 3.3 cell/mm3 CD4 increase (p = 0.06).ConclusionVitamin D3 supplementation was effective in repleting 25(OH)D levels after 24 weeks. Current efavirenz use was positively associated with post-repletion 25(OH)D levels, while greater time on zidovudine was associated with lower post-repletion 25(OH)D levels. The association between improved CD4 recovery and vitamin D repletion suggests a potential benefit of vitamin D supplementation on immunologic recovery during HIV treatment.Trial registrationThis trial is registered at The Brazilian Clinical Trials Registry (U1111‐1165‐2537).Electronic supplementary materialThe online version of this article (doi:10.1186/s12937-015-0072-6) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy

Coelho

Cardoso

Luz

et al. 2015

Nutr J

View full text Add to dashboard Cite

show abstract

“…One study carried out only on female participants [30]. Eight studies used the criteria for diagnosing metabolic syndrome proposed by the NCEP-ATP III [30,35,36,[40][41][42][43][44]; three the criteria of the IDF [31,38,39]; ten studies used International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesit (IDF/NHLBI/AHA/ WHF/IAS/ IASO) [26-28, 32-34, 37, 45-47]; two studies used Joint Interim Statement (JIS) [29,48]; one study used NCEP ATP III and IDF criteria [7]; one study used modified NCEP, IDF and JIS criteria for diagnosing MS [6]; and one study did not present the criteria it used for the diagnosis of MS [49].…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

Prevalence of metabolic syndrome in Brazilian adults in the last 10 years: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

Background A cluster of interconnected cardiometabolic risk factors characterizes metabolic Syndrome (MS). The prevalence of MS is increasing worldwide, but there is not a meta-analysis of this prevalence in the Brazilian population. We aimed to determine the prevalence of metabolic syndrome among adult general population in Brazil through a meta‑analysis study. Methods Original research studies were searched at PubMed, Scopus, Web of Science, and SciELO databases, from 2011 to 2021. We used the Joanna Briggs Institute tool to assess the quality of included studies. The random effect model was used to estimate the pooled prevalence of MS. Subgroup and meta-regression analysis were conducted for explored heterogeneity and used the Funnel Plot and Egger’s test to assess publication bias. The study was performed based on the criteria of Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). Results The search in electronic databases identified 1598 records. From this total, 26 studies were eligible to be included in the final analysis. The overall pooled prevalence among the general population of Brazil was 33% with high heterogeneity observed. By gender, the prevalences were 26% in males and 38% in females. By criteria that was used to define MS, the prevalence were 31% in NCEP ATP III, 25% in JIS, 37% in IDF/NHLBI/AHA/WHF/IAS/IASO and 33% in IDF criteria. The prevalence in different habitat was 34% in urban, 15% in rural, 28% in quilombola and 37% in indigenous. In different regions was 37% in the South, 30% in Southeast, 38% in North, 31% in Northeast and 39% in Midwest. The pooled prevalence of MS with age was < 45 years: 43% and ≥ 45 years: 42% and the prevalence based on year of study implementation was 31% in 2015–2019, 35% in 2010–2014 and 28% in 2005–2009. There were no statistically significant differences between subgroups. Most of the studies showed high quality assessment criteria’s except adequate sample size criteria and many studies participants were not sampled in an appropriate way. Conclusions Our review indicates a high prevalence of MS in the healthy Brazilian adult population, when compared to others countries and with a world estimate.

show abstract

“…The mean age of the study participants was 58.31 ± 9.89 years. Two studies were conducted in Saudi Arabia [37,38], and one study each from Iran [39], Brazil [40], South Korea [41], Belgium [42], and Taiwan [29]. All of these patients had been diagnosed with MetS.…”

Section: Study Patient and Regimen Characteristicsmentioning

confidence: 99%

The Impact of Metabolic Syndrome on Bone Mass in Men: Systematic Review and Meta-Analysis

et al. 2023

View full text Add to dashboard Cite

Studies to date have yielded conflicting results on associations between components of metabolic syndrome (MetS) and bone mineral density (BMD), particularly in men. This current systematic review and meta-analysis addresses the existing gap in the literature and aims to evaluate bone mineral density (BMD) at the femoral neck (FN) and lumbar spine (LS) in men diagnosed with MetS. The two study authors independently searched PubMed, Cinahl, Embase, and Web of Science up to 8 February 2022 for studies in English. The inclusion criteria were (i) diagnosis of MetS according to the NCEP-ATP III 2001 criteria; (ii) adult male demographic; (iii) analyzable data on BMD in at least two sites using dual-energy X-ray absorptiometry (DXA), and (iv) original observational studies. Case reports and non-English articles were excluded. We analyzed the results of seven studies providing data on bone density in men with MetS. Results: Based on random effect weights, the mean BMD of the femoral neck and lumbar spine were 0.84 and 1.02, respectively. The mean lumbar spine T-score was −0.92. In meta-regression analysis, the variances in mean BMD in the lumbar spine and femoral neck could not be significantly explained by BMI (lumbar BMD: Q = 1.10, df = 1, p = 0.29; femoral neck BMD: Q = 0.91, df = 1, p = 0.34). Our meta-analysis suggests normal bone mass in adult males with MetS. Due to the high heterogeneity in the seven analyzed studies and the lack of control groups in these studies, further research is needed to fully elucidate the associations between MetS and its components and BMD in men.

show abstract

Bone mineral density, metabolic syndrome, and vitamin D in indigenous from south of Brazil

Cited by 6 publications

References 21 publications

Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy

Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy

Prevalence of metabolic syndrome in Brazilian adults in the last 10 years: a systematic review and meta-analysis

The Impact of Metabolic Syndrome on Bone Mass in Men: Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About